Advances in DNA repair in cancer therapy
https://libcat.nshealth.ca/en/permalink/provcat32399
Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors.
--New York, NY:
Springer
, c2013.
- Available Online
- View e-Book
- Location
- Online
This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and dow…
- Available Online
- View e-Book
- Other Authors
- Panasci, Lawrence
- Aloyz, Raquel
- Alaoui-Jamali, Moulay
- Responsibility
- Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2013
- Physical Description
- 1 online resource (viii, 312 p. : 35 ill., 25 ill. in color)
- Series Vol.
- 72
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781461447412
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- DNA Repair
- Neoplasms - drug therapy
- Neoplasms - genetics
- Subjects (LCSH)
- Oncology
- Abstract
- This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling is examined.
- Contents
- Repair of DNA interstrand cross-links produced by cancer chemotherapeutic drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- Relationship between DNA-repair genes, cellular radiosensitivity, and the response of tumors annd normal tissues to radiotherapy -- Important roles of ERCCI in DNA repair and targeted therapy -- The role of BRCA1 and BRCA2 in anticancer drug therepy -- DNA-PK in CLL chemotherapy -- Poly (ADP) ribose polymerase at the interface of DNA damage signaling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a therapeutic target -- Telomores, Telomerase, and DNA damage response in cancer therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.
- Format
- e-Book
- Location
- Online
Antiangiogenic Agents in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat40632
edited by Beverly A. Teicher, Lee M. Ellis.
(2nd ed.)
--Totowa, NJ:
Humana Press
, c2008.
- Available Online
- View e-Book
- Location
- Online
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art…
- Available Online
- View e-Book
- Other Authors
- Teicher, Beverly A
- Ellis, Lee M
- Responsibility
- edited by Beverly A. Teicher, Lee M. Ellis
- Edition
- 2nd ed.
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2008
- Physical Description
- 1 online resource (xviii, 559 p. : ill.)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597451840
- 9781588298706 (print ed.)
- Subjects (MeSH)
- Angiogenesis Inhibitors - therapeutic use
- Antineoplastic Agents - therapeutic use
- Neoplasms - drug therapy
- Neovascularization, pathologic - drug therapy
- Abstract
- Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
- Contents
- Part I. Basic Biology of Angiogenesis -- Vascular Endothelial Growth Factor Family and Its Receptors -- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors -- The Role of Integrins in Tumor Angiogenesis -- Tumor Endothelial Cell Abnormalities -- The Extracellular Matrix and VEGF Processing -- Endothelial Precursor Cells -- Role of Pericytes in Angiogenesis -- Newer Vascular Targets -- Chemokines in Angiogenesis -- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis -- Imaging Angiogenesis -- Tumor Blood Vessels -- Lymphatic System in the Pathology of Cancer -- Part II. Translational Research in Tumor Angiogenesis -- VEGF in the Adult -- Normalization of Tumor Vasculature and Microenvironment -- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man -- Small-Molecule Vascular Disrupting Agents in Cancer Therapy -- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents -- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside -- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications -- Part III. Antiangiogenic Therapy in the Clinical Trial Results and Future Directions -- Angiogenesis and Angiogenesis Inhibition in Sarcomas -- Antiangiogenesis Agents in Colorectal Cancer -- Antiangiogenic Therapy for Primary CNS Tumors -- Angiogenesis Inhibitors for the Treatment of Lung Cancer -- Antiangiogenic Therapy of Renal Cell Carcinoma -- Antiangiogenesis Therapies in Gynecologic Malignancies -- Antiangiogenic Agents in Myeloid Malignancies -- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors -- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis -- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- The Role of Imaging in the Clinical Development of Antiangiogenic Agents.
- Format
- e-Book
- Location
- Online
Antibody-drug conjugates and immunotoxins : from pre-clinical development to therapeutic applications
https://libcat.nshealth.ca/en/permalink/provcat32428
Gail Lewis Phillips, editor.
--New York, NY:
Springer
, c2013.
- Available Online
- View e-Book
- Location
- Online
The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under int…
- Available Online
- View e-Book
- Other Authors
- Phillips, Gail Lewis
- Responsibility
- Gail Lewis Phillips, editor
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2013
- Physical Description
- 1 online resource (ix, 372 p. : 88 ill., 45 ill. in color)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781461454564
- Subjects (MeSH)
- Antibodies
- Drug Combinations
- Immunotoxins - therapeutic use
- Neoplasms - drug therapy
- Subjects (LCSH)
- Oncology
- Monoclonal antibodies
- Abstract
- The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
- Contents
- Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins -- Antibody-Drug Conjugate Development -- Components of ADC Development: Assay Methodologies and Challenges -- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates -- Predictive Biomarkers for Antibody-Drug Conjugates -- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates -- Linker Technology and Impact of Linker Design on ADC Properties -- Antibody-drug conjugates for the treatment of B-cell malignancies -- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies -- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies -- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer -- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) -- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer -- EphA2 Immunoconjugate -- Anti-PSMA Antibody-Drug Conjugates -- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine -- Studies on the Metabolism of Antibody-Drug Conjugates -- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu -- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors -- Index
- Format
- e-Book
- Location
- Online
Apoptosis, Senescence, and Cancer
https://libcat.nshealth.ca/en/permalink/provcat29394
edited by David A. Gewirtz, Shawn E. Holt, Steven Grant.
(2nd ed.)
--Totowa, NJ:
Humana Press
, c2007.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Gewirtz, David A
- Other Authors
- Holt, Shawn E
- Grant, Steven
- Responsibility
- edited by David A. Gewirtz, Shawn E. Holt, Steven Grant
- Edition
- 2nd ed.
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2007
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597452212
- Subjects (MeSH)
- Apoptosis
- Cell Aging - drug effects
- Cell Transformation, Neoplastic
- Neoplasms - drug therapy
- Format
- e-Book
- Location
- Online
Biomarkers in breast cancer : molecular diagnostics for predicting and monitoring therapeutic effect
https://libcat.nshealth.ca/en/permalink/provcat22482
Gasparini, Giampietro.
--Totowa, NJ:
Humana Press
, 2006.
- Call Number
- WP 870 B615 2006
- Location
- Dickson Building
- Call Number
- WP 870 B615 2006
- Author
- Gasparini, Giampietro
- Other Authors
- Hayes, Daniel F
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- 2006
- Physical Description
- 341 p.
- Series Title
- Cancer drug discovery and development
- ISBN
- 1588292274
- Subjects (MeSH)
- Breast Neoplasms - diagnosis
- Molecular Diagnostic Techniques
- Tumor Markers, Biological
- Format
- Book
- Location
- Dickson Building
- Loan Period
- 3 weeks
Bladder Tumors : Molecular Aspects and Clinical Management
https://libcat.nshealth.ca/en/permalink/provcat30059
edited by Vinata B. Lokeshwar, Axel S. Merseburger, Stefan H. Hautmann.
--Totowa, NJ:
Springer Science+Business Media
, c2011.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Lokeshwar, Vinata B
- Other Authors
- Merseburger, Axel S
- Hautmann, Stefan H
- Responsibility
- edited by Vinata B. Lokeshwar, Axel S. Merseburger, Stefan H. Hautmann
- Place of Publication
- Totowa, NJ
- Publisher
- Springer Science+Business Media
- Date of Publication
- c2011
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781607619284
- Subjects (MeSH)
- Tumor Markers, Biological
- Urinary Bladder Neoplasms
- Format
- e-Book
- Location
- Online
Bone Metastasis : Experimental and Clinical Therapeutics
https://libcat.nshealth.ca/en/permalink/provcat29113
edited by Gurmit Singh, Shafaat A. Rabbani.
--Totowa, NJ:
Humana Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Singh, Gurmit
- Other Authors
- Rabbani, Shafaat A
- Responsibility
- edited by Gurmit Singh, Shafaat A. Rabbani
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2005
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781592598922
- Subjects (MeSH)
- Bone Neoplasms - secondary
- Neoplasm Metastasis
- Subjects (LCSH)
- Oncology
- Orthopedics
- Format
- e-Book
- Location
- Online
BRAF Targets in Melanoma : Biological Mechanisms, Resistance, and Drug Discovery
https://libcat.nshealth.ca/en/permalink/provcat39005
Ryan J. Sullivan, editor.
--New York, NY:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researcher…
- Available Online
- View e-Book
- Other Authors
- Sullivan, Ryan J
- Responsibility
- Ryan J. Sullivan, editor
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (viii, 204 p. : 26 illus., 21 illus. in color)
- Series Vol.
- 82
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781493921430
- 9781493921423 (print ed.)
- ISSN
- 2196-9906
- Subjects (MeSH)
- Melanoma - drug therapy
- Melanoma - genetics
- Molecular Targeted Therapy - methods
- Protein Kinase Inhibitors - therapeutic use
- Proto-Oncogene Proteins B-raf - antagonists & inhibitors
- Abstract
- This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.
- Contents
- 1. Melanoma: Historical Context -- 2. Melanoma Pathogenesis -- 3. Molecular Diagnostics and Tumor Mutational Analysis -- 4. Clinical Utility of BRAF-Targeted Therapy in Melanoma -- 5. The Ethics of Randomized Trials in Oncology -- 6. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- 7. Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy -- 8. Combination BRAF-Directed Therapy and Immunotherapy -- 9. Moving Forward: Making BRAF-Targeted Therapy Better.
- Format
- e-Book
- Location
- Online
Camptothecins in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat28891
edited by Val R. Adams, Thomas G. Burke.
--Totowa, NJ:
Humana Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Adams, Val R
- Other Authors
- Burke, Thomas G
- Responsibility
- edited by Val R. Adams, Thomas G. Burke
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2005
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781592598663
- Subjects (MeSH)
- Camptothecin - pharmacology
- Camptothecin - therapeutic use
- Neoplasms - drug therapy
- Antineoplastic Agents, Phytogenic - therapeutic use
- Format
- e-Book
- Location
- Online
Cancer Chemoprevention. Vol. 2, Strategies for Cancer Chemoprevention
https://libcat.nshealth.ca/en/permalink/provcat30010
edited by Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman.
--Totowa, NJ:
Humana Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Kelloff, Gary J
- Other Authors
- Hawk, Ernest T
- Sigman, Caroline C
- Responsibility
- edited by Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2005
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781592597680
- Subjects (MeSH)
- Anticarcinogenic Agents - therapeutic use
- Chemoprevention - methods
- Neoplasms - prevention & control
- Format
- e-Book
- Location
- Online
Cancer Drug Resistance
https://libcat.nshealth.ca/en/permalink/provcat28300
edited by Beverly A. Teicher.
--Totowa, NJ:
Humana Press
, c2006.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Teicher, Beverly A
- Responsibility
- edited by Beverly A. Teicher
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2006
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597450355
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Drug Resistance, Neoplasm
- Format
- e-Book
- Location
- Online
Cancer Proteomics : From Bench to Bedside
https://libcat.nshealth.ca/en/permalink/provcat40631
edited by Sayed S. Daoud.
--Totowa, NJ:
Humana Press
, c2008.
- Available Online
- View e-Book
- Location
- Online
Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current st…
- Available Online
- View e-Book
- Other Authors
- Daoud, Sayed S
- Responsibility
- edited by Sayed S. Daoud
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2008
- Physical Description
- 1 online resource (xii, 264 p. : 5 illus. in color)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597451697
- 9781588298584 (print ed.)
- Subjects (MeSH)
- Antineoplastic Agents
- Biomarkers, Tumor
- Neoplasms
- Proteomics - methods
- Abstract
- Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
- Contents
- Part I. Proteomics Technologies -- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses -- Part II. Cell Signaling Proteomics -- Integration of Genomics and Proteomics in Dissecting p53 Signaling -- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy -- Part III. Tumor Proteomics -- Oncoproteomics for Personalized Management of Cancer -- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors -- Insight on Renal Cell Carcinoma Proteome -- Proteomics in Lung Cancer -- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia -- New Tumor Biomarkers: Practical Considerations Prior to Clinical Application -- Part IV. Bioinformatics and Regulatory Aspects of Proteomics -- Annotating the Human Proteome: From Establishing a Parts List to a Tool for Target Identification -- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview.
- Format
- e-Book
- Location
- Online
Checkpoint Controls and Targets in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat29742
edited by Zahid H. Siddik.
--Totowa, NJ:
Humana Press
, c2009.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Siddik, Zahid H
- Responsibility
- edited by Zahid H. Siddik
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2009
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781607611783
- Subjects (MeSH)
- Antineoplastic Agents - pharmacology
- Cell Cycle Checkpoints
- Cell Cycle - drug effects
- Neoplasms - drug therapy
- Format
- e-Book
- Location
- Online
Chemokine Receptors in Cancer
https://libcat.nshealth.ca/en/permalink/provcat40943
Amy M. Fulton, editor.
--New York, NY:
Humana Press
, c2009.
- Available Online
- View e-Book
- Location
- Online
Chemokine Receptors in Cancer summarizes the growing body of evidence that several chemokine receptors contribute to tumor behavior. Chemokine receptors were first identified on leukocytes and mediate directed migration of many host cells to sites of ligand expression. It is now well established that most malignant cells also express one or more chemokine receptor. This book describes our current understanding regarding how chemokine receptors contribute to tumor cell migration as well as cell …
- Available Online
- View e-Book
- Other Authors
- Fulton, Amy M
- Responsibility
- Amy M. Fulton, editor
- Place of Publication
- New York, NY
- Publisher
- Humana Press
- Date of Publication
- c2009
- Physical Description
- 1 online resource (x, 176 p. : 13 illus.)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781603272674
- 9781603272667 (print ed.)
- Subjects (MeSH)
- Angiogenesis Inducing Agents
- Neoplasms
- Receptors, Chemokine - drug effects
- Abstract
- Chemokine Receptors in Cancer summarizes the growing body of evidence that several chemokine receptors contribute to tumor behavior. Chemokine receptors were first identified on leukocytes and mediate directed migration of many host cells to sites of ligand expression. It is now well established that most malignant cells also express one or more chemokine receptor. This book describes our current understanding regarding how chemokine receptors contribute to tumor cell migration as well as cell survival and proliferation. The function of chemokine receptors expressed on host cells including antitumor immune effector cells as well as angiostatic and angiogeneic functions of chemokines acting on endothelial cells are described. The role of chemokine receptors that act as decoy receptors is also summarized. The therapeutic potential and challenges of targeting chemokine receptors or cognate ligands is also addressed.
- Contents
- Chemokines and Chemokine Receptors in Cancer Progression -- CXCR4 and Cancer -- HIF-1 Regulation of Chemokine Receptor Expression -- Chemokine Receptors Involved in Colon Cancer Progression, and Lymph Node Metastasis -- The CXCR3/CXCL3 Axis in Cancer -- Roles for CCR7 in Cancer Biology -- The CCL5/CCR5 Axis in Cancer -- CXC Chemokines in Cancer Angiogenesis -- The Roles of Chemokines and Chemokine Receptors in Prostate Cancer.
- Format
- e-Book
- Location
- Online
Combination Cancer Therapy : Modulators and Potentiators
https://libcat.nshealth.ca/en/permalink/provcat29068
edited by Gary K. Schwartz.
--Totowa, NJ:
Humana Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Schwartz, Gary K
- Responsibility
- edited by Gary K. Schwartz
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2005
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781592598649
- Subjects (MeSH)
- Drug Therapy, Combination
- Neoplasms - drug therapy
- Format
- e-Book
- Location
- Online
Cytokines in the Genesis and Treatment of Cancer
https://libcat.nshealth.ca/en/permalink/provcat40580
edited by Michael A. Caligiuri, Michael T. Lotze.
--Totowa, NJ:
Humana Press
, c2007.
- Available Online
- View e-Book
- Location
- Online
Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. Divided into four sections, the volume's first three parts focus on cytokines in the genesis of cancer. The final section describes the notable progress--both in animal models and humans--in demonstrating the use …
- Available Online
- View e-Book
- Other Authors
- Caligiuri, Michael A
- Lotze, Michael T
- Responsibility
- edited by Michael A. Caligiuri, Michael T. Lotze
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2007
- Physical Description
- 1 online resource (xix, 482 p.)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597454551
- 9780896038202 (print ed.)
- Subjects (MeSH)
- Cytokines - immunology
- Cytokines - therapeutic use
- Neoplasms - genetics
- Neoplasms - therapy
- Abstract
- Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. Divided into four sections, the volume's first three parts focus on cytokines in the genesis of cancer. The final section describes the notable progress--both in animal models and humans--in demonstrating the use of cytokine or anticytokine therapies for the prevention and treatment of cancer. Cytokines in the Genesis and Treatment of Cancer brings together an impressive array of internationally distinguished investigators who are devoted to the study of cytokines and cancer. Together, they produce an insightful, comprehensive discussion of cytokines and cancer that will serve as the perfect reference for all those working in the field.
- Contents
- I. Infectious Agents, Cytokines, and Cancer -- Helicobacter pylori and Cytokines in the Genesis of Gastric Cancer -- HTLV-1, Cytokines,and Cancer -- Herpesviruses, Cytokines, and Cancer -- II. Cytokines and Carcinogenesis -- Tumor Necrosis Factor and Cancer -- Transforming Growth Factor-ß and Cancer -- Interleukin-1 Family of Cytokines and Cancer -- Interleukin-4/13 and Cancer -- Interleukin-6 and Castleman's Disease -- Interleukin-10 (IL-10) -- Cytokines in Multiple Myeloma -- In Vivo Murine Cytokine Models and the Genesis of Cancer -- Experimental Models of Cytokines and Cancer Prevention -- III. Cytokines and Tumor Stroma/Metastasis -- Cytokines in the Tumor Stroma -- Cytokines and Tumor Angiogenesis -- Chemokine and Receptor Expression in Tumor Progression -- The Biology of Cancer Cachexia and the Role of TNF-a -- IV. Cytokines in the Treatment of Cancer -- Interleukin-2 and Cancer Therapy -- Interleukin-12 and Cancer Therapy -- The Type I Interferon System With Emphasis on Its Role in Malignancies -- Combination Cytokine Therapy -- Novel Strategies for Cytokine Administration Via Targetting -- Cytokines and Cancer Vaccines -- Anticytokine Treatment -- Cytokines in the Supportive Care of Cancer.
- Format
- e-Book
- Location
- Online
Death Receptors in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat28642
edited by Wafik S. El-Deiry.
--Totowa, NJ:
Humana Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- El-Deiry, Wafik S
- Responsibility
- edited by Wafik S. El-Deiry
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2005
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781592598519
- Subjects (MeSH)
- Cell Death - immunology
- Genetic therapy - methods
- Neoplasms - immunology
- Neoplasms - therapy
- Receptors, Tumor Necrosis Factor
- Subjects (LCSH)
- Oncology
- Immunology
- Gene therapy
- Format
- e-Book
- Location
- Online
Developments in T Cell Based Cancer Immunotherapies
https://libcat.nshealth.ca/en/permalink/provcat39372
Paolo A. Ascierto, David F. Stroncek, Ena Wang, editors.
(1st ed.)
--Cham:
Springer International Publishing : Imprint: Humana Press
, c2015.
- Available Online
- View e-Book
- Location
- Online
This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification …
- Available Online
- View e-Book
- Other Authors
- Ascierto, Paolo A
- Stroncek, David F
- Wang, Ena
- Responsibility
- Paolo A. Ascierto, David F. Stroncek, Ena Wang, editors
- Edition
- 1st ed.
- Place of Publication
- Cham
- Publisher
- Springer International Publishing : Imprint: Humana Press
- Date of Publication
- c2015
- Physical Description
- 1 online resource (xv, 305 p. : 26 illus. in color)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9783319211671
- 9783319211664 (print ed.)
- ISSN
- 2196-9906
- Subjects (MeSH)
- Immunity, Cellular - immunology
- Immunotherapy - methods
- Neoplasms - immunology
- Neoplasms - therapy
- T-Lymphocytes - immunology
- Abstract
- This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.
- Contents
- 1. Insights on Peptide Vaccines in Cancer Immunotherapy -- 2. Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer -- 3. T Cell Fate in the Tumor Microenvironment -- 4 Influence of Antigen Receptor Avidity, Affinity, and Specificity on Genetically Engineered T Cells -- 5. Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy -- 6. Production of Clinical T Cell Therapies -- 7. Clinical Success of Adoptive Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes -- 8. Harnessing Stem Cell-Like Memory T Cells for Adoptive Cell Transfer Therapy of Cancer -- 9. T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy -- 10. T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer -- 11. Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies -- 12. Chimeric Antigen Receptor (CAR) T Cells -- 13. Rapamycin-Resistant T Cells and Pentostatin- Based Immuno-Selective Conditioning for the Allogeneic T Cell Therapy of Cancer.
- Format
- e-Book
- Location
- Online
DNA and Histone Methylation as Cancer Targets
https://libcat.nshealth.ca/en/permalink/provcat41841
Atsushi Kaneda, Yu-ichi Tsukada, editors.
--Cham:
Humana Press
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book will focus on DNA and histone methylation in epigenetics and describe how it is involved in the molecular mechanisms responsible for the development of cancer. Chapters will summarize the current knowledge of the molecular basis of DNA and histone methylation and explain how it is involved in cancer, describe the features of DNA and histone methylation associated with particular types of cancer, diagnostic/therapeutic applications, and future directions of DNA and histone methylation …
- Available Online
- View e-Book
- Other Authors
- Kaneda, Atsushi
- Tsukada, Yu-ichi
- Responsibility
- Atsushi Kaneda, Yu-ichi Tsukada, editors
- Place of Publication
- Cham
- Publisher
- Humana Press
- Date of Publication
- 2017
- Physical Description
- 1 online resource (viii, 624 pages) : 91 illus., 81 illus. in color
- Series Title
- Cancer drug discovery and development
- ISBN
- 9783319597867
- 9783319597843 (print ed.)
- ISSN
- 2196-9906
- Subjects (MeSH)
- DNA Methylation
- Epigenesis, Genetic
- Histones
- Molecular Targeted Therapy
- Neoplasms - genetics
- Abstract
- This book will focus on DNA and histone methylation in epigenetics and describe how it is involved in the molecular mechanisms responsible for the development of cancer. Chapters will summarize the current knowledge of the molecular basis of DNA and histone methylation and explain how it is involved in cancer, describe the features of DNA and histone methylation associated with particular types of cancer, diagnostic/therapeutic applications, and future directions of DNA and histone methylation as cancer targets.
- Contents
- DNA and histone methylation in epigenetics -- The molecular basis of DNA methylation -- The molecular basis of DNA demethylation -- DNA methylation changes in cancer -- Misregulation of DNA methylation regulators in cancer -- The molecular basis of histone methylation -- The molecular basis of histone demethylation -- Misregulation of histone methylation regulators in cancer -- Other histone modifications -- DNA methylation and dysregulation of miRNA in cancer -- Genomic imprinting syndromes and cancer -- DNA and histone methylation in brain cancer -- DNA and histone methylation in gastric cancer -- DNA and histone methylation in hematopoietic malignancy -- DNA and histone methylation in lung cancer -- DNA and histone methylation in liver cancer -- DNA and histone methylation in colon cancer -- DNA and histone methylation in prostate cancer -- DNA and histone modifications in cancer diagnosis -- DNA and histone modifications in cancer therapy -- Future perspective of DNA and histone methylation as cancer targets.
- Format
- e-Book
- Location
- Online
DNA Topoisomerases and Cancer
https://libcat.nshealth.ca/en/permalink/provcat30911
Yves Pommier, editor.
--New York, NY:
Humana Press
, c2012.
- Available Online
- View e-Book
- Location
- Online
DNA topoisomerases are present in all living organisms and are essential to maintaining the helical structure of DNA. They are highly relevant for cancer because a number of anti-cancer drugs selectively target two of the human enzymes, DNA topoisomerases I and II. Those drugs convert topoisomerases into cellular poisons by trapping the enzymes as they cleave DNA. The book starts out with a detailed outline of the phyllogeny of the different topoisomerases, continues with recent studies on the …
- Available Online
- View e-Book
- Other Authors
- Pommier, Yves
- Responsibility
- Yves Pommier, editor
- Place of Publication
- New York, NY
- Publisher
- Humana Press
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xi, 443 p. : 65 ill., 49 ill. in color)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781461403234
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- DNA Topoisomerases - chemistry
- DNA Topoisomerases - genetics
- Neoplasms - drug therapy
- Topoisomerase Inhibitors
- Subjects (LCSH)
- Oncology
- Biochemistry
- Genetics
- Abstract
- DNA topoisomerases are present in all living organisms and are essential to maintaining the helical structure of DNA. They are highly relevant for cancer because a number of anti-cancer drugs selectively target two of the human enzymes, DNA topoisomerases I and II. Those drugs convert topoisomerases into cellular poisons by trapping the enzymes as they cleave DNA. The book starts out with a detailed outline of the phyllogeny of the different topoisomerases, continues with recent studies on the crystal structures of the human topoisomerases, and their biochemistry. The following section reviews the chemical biology of the topoisomerase inhibitors used in cancer chemotherapy and the implication of topoisomerases in generating recombinations and DNA damage. The third section summarizes the current use of the various topoisomerase inhibitors in cancer chemotherapy. And finally, the last section includes several chapters describing the DNA repair pathways for topoisomerase-induced DNA damage. This book is intended for students and faculty but also for health care professionals who wish to have a self-contained and up-to-date information on topoisomerases. Chapters have been written by leaders and world reknowned experts in the topoisomerase field.
- Contents
- Introduction and Historical Perspective -- Human DNA topoisomerase I: Structure, Enzymology and Biology -- Mitochondrial topoisomerases -- Structure and mechanism of eukaryotic type IIA topoisomerases -- Essential functions of topoisomerase III[alpha] in the nucleus and mitochondria -- DNA topoisomerase I and illegitimate recombination -- Topoisomerase-induced DNA damage -- Topoisomerases and carcinogenesis: Topoisomerase III[alpha] and BLM -- Topoisomerase inhibitors: a paradigm for interfacial inhibitors -- Topoisomerase I inhibitors: chemical biology -- Topoisomerase II inhibitors: chemical biology -- Topoisomerase I inhibitors: current use and prospects -- Topoisomerase II inhibitors: current use and prospects -- Transcription stress by camptothecin: mechanism and implication for the drug antitumor activity -- Mechanism regulating cellular responses to DNA topoisomerase I-targeted agents -- Tyrosyl-DNA-phosphodiesterase -- Ubiquitin and ubiquitin-like proteins in repair of topoisomerase-mediated DNA damage -- Repair of topoisomerase II-mediated DNA damage: fixing DNA damage arising from a protein covalently trapped on DNA -- Topoisomerases and Apoptosis -- Index.
- Format
- e-Book
- Location
- Online
